Literature DB >> 28441276

AUGS Consensus Statement: Association of Anticholinergic Medication Use and Cognition in Women With Overactive Bladder.

.   

Abstract

Overactive bladder affects a significant portion of the overall population and has substantial impact on daily activities and quality-of-life. When considering treatment, behavioral therapies should be instituted first, followed by medical therapies. Anticholinergic medications and beta-3 agonists are often used as initial pharmacologic therapy, but caution should be taken in prescribing anticholinergic medications in frail or cognitively impaired patients. Recently, concerns have developed regarding anticholinergic medications and the associated risk of cognitive impairment, dementia, and Alzheimer disease in the general population. Given the available evidence, which has shown significant associations between anticholinergic medication use and increased risk of cognitive impairment and dementia, providers should counsel on the associated risks, prescribe the lowest effective dose, and consider alternative medications in patients at risk.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28441276     DOI: 10.1097/SPV.0000000000000423

Source DB:  PubMed          Journal:  Female Pelvic Med Reconstr Surg        ISSN: 2151-8378            Impact factor:   2.091


  6 in total

1.  A cost-effectiveness analysis of Onabotulinumtoxin A as first-line treatment for overactive bladder.

Authors:  Jonathan P Shepherd; Charelle M Carter-Brooks; Christopher Chermanksy
Journal:  Int Urogynecol J       Date:  2018-04-18       Impact factor: 2.894

2.  Effect of Behavioral and Pelvic Floor Muscle Therapy Combined With Surgery vs Surgery Alone on Incontinence Symptoms Among Women With Mixed Urinary Incontinence: The ESTEEM Randomized Clinical Trial.

Authors:  Vivian W Sung; Diane Borello-France; Diane K Newman; Holly E Richter; Emily S Lukacz; Pamela Moalli; Alison C Weidner; Ariana L Smith; Gena Dunivan; Beri Ridgeway; John N Nguyen; Donna Mazloomdoost; Benjamin Carper; Marie G Gantz
Journal:  JAMA       Date:  2019-09-17       Impact factor: 56.272

3.  Advances in pharmacotherapy for the treatment of overactive bladder.

Authors:  Caitlyn E Painter; Anne M Suskind
Journal:  Curr Bladder Dysfunct Rep       Date:  2019-11-25

4.  Anticholinergic burden in older adult inpatients: patterns from admission to discharge and associations with hospital outcomes.

Authors:  Maria Herrero-Zazo; Rachel Berry; Emma Bines; Debi Bhattacharya; Phyo K Myint; Victoria L Keevil
Journal:  Ther Adv Drug Saf       Date:  2021-05-06

5.  Protocol for a multicenter randomized, double blind, controlled pilot trial of higher neural function in overactive bladder patients after anticholinergic, beta-3 adrenergic agonist, or placebo.

Authors:  Rachel A High; Jill M Danford; Zhaoyue Shi; Christof Karmonik; Thomas J Kuehl; Erin T Bird; Rose Khavari
Journal:  Contemp Clin Trials Commun       Date:  2020-07-14

6.  Feasibility of Self-administered Neuromodulation for Neurogenic Bladder in Spinal Cord Injury.

Authors:  Argyrios Stampas; Rose Khavari; Joel E Frontera; Suzanne L Groah
Journal:  Int Neurourol J       Date:  2019-09-30       Impact factor: 2.835

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.